Biotech IV Monitor

KRYS — Krystal Biotech Inc.

$9.9B market cap · 4 upcoming readouts tracked

Clinical trial readout dates for Krystal Biotech Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts41 Phase 3
Market cap$9.9B
Cash & investments$912Mas of Sep 30, 2026
Recent 8-K filings1latest 2026-11-02

Upcoming readouts

Phase 3 KB803
Dystrophic Epidermolysis Bullosa; DEB - Dystrophic Epidermolysis Bullosa · NCT07016750
December 2026
Recruiting
Phase 1/2 KB801
Neurotrophic Keratitis · NCT06999733
December 2026
Recruiting
Phase 1/2 KB707
Lung Cancer, Non-small Cell; Lung Cancer Metastatic · NCT06228326
February 2027
Recruiting
Phase 1/2 KB707
Cancer; Melanoma Stage III · NCT05970497
July 2027
Recruiting

Cash position

Krystal Biotech Inc. reported $912M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-02). It reported net income of $63M for that quarter.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-02

Companies working on similar indications

Discussion

No messages yet. If you follow KRYS, you can start the conversation.
Track KRYS in real time
See live implied volatility for KRYS and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on KRYS
Contact — questions or corrections about KRYS: dukeupt@gmail.com